Obesia -Lily Obesity tablets indicate promising weight loss in new results
A test pill According to preliminary tests announced by the pharmacy on Thursday, Eli Lily led to average weight loss of more than 12 % of body weight in people with obesity. This tablet is taken daily and a replacement for the company’s popular weather drug will be an injectable drug once a week.
In the name of OrForglipron, this is part of a growing class of drugs known as GLP-1s, which includes Ozempic Novo Nordisk and Wegovy. These drugs imitate the body’s natural hormone, which helps regulate blood sugar and promotes the feeling of fullness. GLP-1 injected drugs have shown weight loss of about 15 to 20 percent.
The 18 -month trial of Eli Lily consisted of more than 3,000 adults with an average starting weight of 228 pounds and 37 body mass index, which is obese. Participants were randomized to receive 6, 12 or 36 mg orforglipron or placebo tablets. The lowest dose of Orforglipron resulted in a decrease in less than 8 % body weight or about 18 pounds, and the middle dose resulted in a 9 % or 21 pound decrease.
The highest dose resulted in weight loss an average of 12 % or about 27 pounds compared to 2 pounds with placebo. In the highest dose group, about 60 percent of the participants lost at least 10 % of their body weight, while 40 % lost 15 % or more.
The participants, who received OrForglipron, began the study at a dose of 1 mg daily and then increased the dose to their final maintenance every four weeks. All in this trial, including placebo groups, a healthy diet and physical activity were also prescribed. There was no restriction of food and water for taking pills.
The pill was safe, but like GLP-1 injected drugs, OrForglipron, the gastrointestinal tract has caused many participants. It was the most common nausea that suffered one -third of the highest dose participants. Constipation was experienced by about a quarter of patients in that group, such as diarrhea and vomiting. These side effects resulted in more than 20 % of participants in each dose group during the study.
Eli Lily says more accurate results are presented in September at the European Association to study the annual diabetes session and are published in a journal reviewed by peers. Novo Nordisk has GLP-1 tablet for diabetes, Rybelsus, but it is not effective for weight loss and has never been approved for weight management.
Orforglipron also looks promising as a diabetes treatment. In a new study published in the Journal of New England Medicine, the tablet reduces blood sugar levels and weight in people with type 2 diabetes. Eli Lily says he plans to submit orforglipron by the end of the year to review.
Novo Nordisk has GLP-1 tablet for diabetes, Rybelsus, but it is not effective for weight loss and has never been approved for weight management. A challenge in preparing a more effective pill how to improve its bioavailability – the amount of drug that enters the circulatory and has an active effect. Other GLP-1 drugs are made up of larger molecules that are not easily absorbed into the gastrointestinal tract. Instead, most of the drug is digested. Eli Lily may solve this problem with Orforglipron, a small molecule formula.
